Back to Psoriasis and a Psoriatic Arthritis Research, Cure, and Care Act (PPARCCA) of 2007

PPARCCA BILL

Bill Summary
The Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007
(H.R. 1188/S. 1459)

SECTION 1. SHORT TITLE
The Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act (PPARCCA)

SECTION 2. TABLE OF CONTENTS
Section 1. Short Title
Section 2. Table of Contents
Section 3. Findings

SECTION 3. FINDINGS
TITLE I—EXPANDING AND IMPROVING RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS
Section 101. EXPANSION OF BIOMEDICAL RESEARCH
• Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand
and intensify research on psoriasis and psoriatic arthritis.
• Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and
offices with respect to psoriasis and psoriatic arthritis research.

Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS
EPIDEMIOLOGY
• Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national
organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national
psoriasis and psoriatic arthritis patient registry.

Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS
SUMMIT
• Directs the Department of Health and Human Services (HHS) to convene a summit of researchers,
public health professionals, patient advocacy organizations, academic institutions, and Federal and
State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis
research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for
Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration,
and the Health Resources and Services Administration, and other federal agencies whose work
involves psoriasis and psoriatic arthritis related co-morbidities.
• Requires a report to Congress – not later than 180 days after the convening of summit.

Section 104. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE
• Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a
study to evaluate and make recommendations to address the following:
(1) The extent to which public and private insurers cover prescription medications and other
treatments for psoriasis and psoriatic arthritis;
(2) The payment structures, such as deductibles and co-payments, amounts and duration of the
coverage and payments under health plans and their adequacy to cover the costs of providing
ongoing care to patients with psoriasis and psoriatic arthritis;
(3) Health plan and insurer coverage policies and practices and their impact on patient access to the
best regimen and most appropriate care for their particular disease state.

to comment